- Humanigen (HGEN +6.4%) has announced treatment of its first COVID-19 patient with lenzilumab in Phase 3 trial, at MedStar Washington Hospital Center, one of 18 sites in the U.S. approved to enroll eligible patients to study lenzilumab, designed specifically to cytokine storm (harmful inflammation).
- The primary objective of the trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster.
- https://seekingalpha.com/news/3629230-dosing-underway-in-lenzilumab-late-stage-study-in-covidminus-19
Friday, October 30, 2020
Dosing underway in Humanigen lenzilumab late-stage study in COVID-19
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.